The average one-year price target for Biodesix (NasdaqGM:BDSX) has been revised to $35.70 / share. This is an increase of 1,900.00% from the prior estimate of $1.78 dated September 10, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $30.30 to a high of $42.00 / share. The average price target represents an increase of 361.24% from the latest reported closing price of $7.74 / share.
What is the Fund Sentiment?
There are 55 funds or institutions reporting positions in Biodesix. This is an decrease of 21 owner(s) or 27.63% in the last quarter. Average portfolio weight of all funds dedicated to BDSX is 0.04%, an increase of 57.75%. Total shares owned by institutions decreased in the last three months by 33.15% to 35,735K shares. 
The put/call ratio of BDSX is 0.08, indicating a bullish outlook.
What are Other Shareholders Doing?
Telemark Asset Management holds 8,282K shares representing 106.19% ownership of the company. No change in the last quarter.
BRYN MAWR TRUST holds 6,095K shares representing 78.14% ownership of the company. No change in the last quarter.
Birchview Capital holds 5,736K shares representing 73.54% ownership of the company. No change in the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,297K shares representing 29.45% ownership of the company. No change in the last quarter.
Perceptive Advisors holds 2,174K shares representing 27.87% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
